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dynamometry group. Although the randomiza-
tion was done in a strict manner, differences may 
still occur, and we regret that these between-
group differences were not noted in the footnote 
to Table 1.
There is debate about whether baseline crite-
ria should be incorporated into the analysis of 
clinical trials. When we included the presence of 
hypertensive disorders and diabetes in a logistic 
model estimating the effect of the use of a pres-
sure catheter, we still found no significant dif-
ferences in rates of instrumental delivery or 
neonatal outcomes between the two study 
groups.
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Hypofractionated Radiotherapy for Breast Cancer
To the Editor: Whelan et al. (Feb. 11 issue)1 
report 10-year results of hypofractionated radio-
therapy, as compared with standard radiotherapy, 
in women with early breast cancer. The study 
showed no overall evidence of inferiority of the 
abbreviated 16-fraction test schedule. However, a 
retrospective subgroup analysis suggested that 
hypofractionation might be relatively less effec-
tive in patients with grade 3 tumors. 
We tested this hypothesis in a meta-analysis 
of the UK Standardisation of Breast Radiotherapy 
(START) A and B trials2,3 and their pilot study.4 
At 5 years, the rates of locoregional relapse were 
4.9% (95% confidence interval [CI], 4.0 to 5.9) in 
patients on the control schedule and 5.2% (95% 
CI, 4.5 to 6.0) in those on the combined hypo-
fractionated schedules. A total of 4883 patients 
with known tumor grade were available for analy-
sis, including 222 with locoregional relapse, with 
a median follow-up of 8 years. Hazard ratios for 
the combined hypofractionated schedules, as com-
pared with the control schedules, were 1.28 (95% 
CI, 0.87 to 1.88) for grade 1 and 2 tumors and 
0.83 (95% CI, 0.56 to 1.23) for grade 3 tumors 
(P = 0.12 for interaction). Adjusted α/β values (in-
dicating sensitivity to fraction size) were estimated 
as 3.6 Gy (95% CI, 0 to 7.4) for grade 1 and 2 
tumors and 2.2 Gy (95% CI, 0 to 5.5) for grade 
3 tumors. Our results suggest that the response 
to radiotherapy fraction size is not affected by 
tumor grade. 
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The authors reply: In the meta-analysis by 
Haviland et al., there was no difference in out-
comes between hypofractionated and convention-
al radiotherapy in patients with high-grade tumors. 
The purpose of our exploratory subgroup analysis 
was to examine the consistency of the treatment 
effect across different risk groups. Hypofraction-
ated radiotherapy was similar to conventional 
radiotherapy in patients under the age of 50 years 
who had tumors of more than 2 cm in diameter 
that were estrogen-receptor–negative or who re-
ceived systemic therapy, but it was less effective 
in those with high-grade tumors. Can our find-
ings be reconciled with the results of the meta-
analysis? 
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Cross-study comparisons are limited. There 
are important differences between the U.K. and 
Canadian trials that could account for the dis-
crepancy in findings (e.g., a shorter follow-up, 
inclusion of node-positive patients, and the use 
of boost radiation and anthracyclines).1-3 Further-
more, our analysis on tumor grade was post hoc 
and only one of five factors that we considered. 
The differential effect between treatments in pa-
tients with high-grade tumors requires validation 
through future research. Meanwhile, we believe 
it is premature to make any decisions concern-
ing the avoidance of hypofractionated radiation 
in treating women with high-grade tumors.
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Alzheimer’s Disease
To the Editor: In their article on Alzheimer’s 
disease, Querfurth and LaFerla (Jan. 28 issue)1 
stated that “the level of muscarinic acetylcholine 
receptors, or receptor coupling, is reduced in the 
brains of patients with Alzheimer’s disease.” How-
ever, a recent review indicated that not all studies 
reported such reductions and that they may not 
occur until the disease is advanced.2 Current study 
methods do not generally allow determination of 
muscarinic type 1 (M1) receptor density or recep-
tor coupling status in specific neuronal path-
ways. In fact, in vivo studies suggest an apparent 
increased sensitivity to some of the effects of the 
M1 agonist arecoline in relatively early stages of 
Alzheimer’s disease.3,4 Presynaptic M1 receptors 
in CA3 pyramidal neurons of the hippocampus 
have been shown to play a critical role in meta-
botropic glutamate receptor-mediated long-term 
depression of Schaffer collaterals.5 Thus, if con-
firmed, hypersensitivity of M1 receptors in Alz-
heimer’s disease, especially in this neuronal path-
way, could be an additional mechanism that 
contributes to synaptic failure and memory dys-
function in Alzheimer’s disease.
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To the Editor: I wonder whether Querfurth and 
LaFerla have an opinion as to whether Alzhei-
mer’s is a single disease. Could it be that there 
are multiple causes of Alzheimer’s “disease,” some 
of which respond better, albeit still poorly, to 
some interventions than others — hence the var-
iable progression of the syndrome? Might we be 
wiser to call it Alzheimer’s syndrome?
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The authors Reply: The question of the level 
and function of muscarinic acetylcholine receptors 
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